GlassScriptPhysician profile
Alessandra Inez Lopez
NPI 1396402715
$3,387.10
in general payments reported to CMS, 2019-2025
14 companies · $1,528 in 2025
The $1,528 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $702 · 2023: $784 · 2024: $123 · 2025: $1,528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164 · Long Term Medical Supply Or Device Loan: $997 · Education: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.07 |
| Long Term Medical Supply Or Device Loan | $997.00 |
| Education | $273.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $997.00 | 2025 | |
| Merck Sharp & Dohme LLC | $524.84 | 2022-2025 | Lynparza, Keytruda |
| Seagen INC. | $327.68 | 2023 | Tukysa |
| Jazz Pharmaceuticals INC. | $248.03 | 2021-2023 | |
| Daiichi Sankyo INC. | $223.71 | 2022-2025 | Datroway |
| Puma Biotechnology, INC. | $219.43 | 2022-2025 | |
| Gilead Sciences, INC. | $161.87 | 2022-2024 | Trodelvy |
| Janssen Biotech, INC. | $154.04 | 2021-2024 | Erleada |
| Stemline Therapeutics INC. | $125.00 | 2025 | Elzonris |
| Genentech USA, INC. | $115.70 | 2022 | |
| Lilly USA, LLC | $110.81 | 2022 | |
| G1 Therapeutics, INC. | $77.34 | 2022 | |
| Pharmacosmos Therapeutics INC. | $57.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $44.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alessandra Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.